Floatz logo

Young Til

Oropharyngeal Cancer

National Cancer Institute (NCI)Cell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Oropharyngeal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
HRYZ Biotech Co.
Phase 2BB
Fludarabine
HRYZ Biotech Co.
Phase 2BB
Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2B
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
National Cancer Institute (NCI)
Phase 2B

View all 23 →

Same molecule, other indications

Young Til is also rated in:

skin cancerDormant
B
Indicative ·
57 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
57 / 100
View asset →
vaginal cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →